Organization
IconOVir Bio
1 clinical trial
2 abstracts
Clinical trial
Phase 1 First-in-Human Dose Escalation and Expansion Study to Assess Safety and Tolerability of Intravenous Administration of ICVB-1042 in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2026-12-01
Abstract
Characterizing the tumor selectivity of oncolytic adenovirus ICVB-1042: Analysis of S-phase induction, viral replication, and cytolytic activity in human primary normal cell types.Org: IconOVir Bio, CellTx Consulting, LLC,